Highly rated in
Highly rated in
Check Dr. Elizabeth T. Loggers' experience treating your condition:
About Dr. Elizabeth T. Loggers

Elizabeth Loggers is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Loggers has been practicing medicine for over 19 years and is highly rated in 34 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Epithelioid Sarcoma, Bone Marrow Transplant, and Liver Embolization. She is licensed to treat patients in Massachusetts and Washington. Loggers is currently accepting new patients.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 6 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Elizabeth T. Loggers it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Elizabeth T. Loggers accepts the following insurance:

  •  Ambetter
  •  Premera

Call to see if your plan is accepted.
825 Eastlake Ave E, Seattle, WA 98109
Background & Education
Graduate Institution
University Of Minnesota Medical School, 2003
Hematology Oncology
Internal Medicine in MA
Hospital Affiliations
Seattle Cancer Care Alliance
St Anne Hospital
UW Medical Center - Montlake
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
View 5 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors